Company profile for HCW Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

HCW Biologics is an innovative immunotherapy company developing novel therapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including...
HCW Biologics is an innovative immunotherapy company developing novel therapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. The core of HCW’s discovery and development efforts revolves around the company’s internally developed Tissue

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2929 N Commerce Parkway Miramar, FL 33025
Telephone
Telephone
(954) 842-2024
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/19/3190945/0/en/HCW-Biologics-Enters-into-4-0-Million-Warrant-Inducement-Priced-At-the-Market-Under-Nasdaq-Rules.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/18/3189881/0/en/HCW-Biologics-Announces-Initiation-of-First-In-Human-Clinical-Trial-to-Evaluate-HCW9302-in-an-Autoimmune-Disease.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188638/0/en/HCW-Biologics-Reports-Third-Quarter-2025-Business-Highlights-and-Financial-Results.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184373/0/en/HCW-Biologics-Shares-the-Latest-Data-for-its-Second-Generation-Immune-Checkpoint-Inhibitor-Presented-at-the-40th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183532/0/en/HCW-Biologics-Presents-Preclinical-Data-for-TRBC-Based-T-Cell-Engager-Program-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-40th-Annual-Meeting.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/22/3171189/0/en/HCW-Biologics-Inc-NASDAQ-HCWB-Participates-in-Virtual-Investor-What-This-Means-Segment.html

GLOBENEWSWIRE
22 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty